Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

9.9K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.9K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

11.5K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
11.5K
Multi-input and Multi-variable systems01:22

Multi-input and Multi-variable systems

428
Cruise control systems in cars are designed as multi-input systems to maintain a driver's desired speed while compensating for external disturbances such as changes in terrain. The block diagram for a cruise control system typically includes two main inputs: the desired speed set by the driver and any external disturbances, such as the incline of the road. By adjusting the engine throttle, the system maintains the vehicle's speed as close to the desired value as possible.
In the absence of...
428
Proteins: From Genes to Degradation02:11

Proteins: From Genes to Degradation

14.6K
Within a biological system, the DNA encodes the RNA, and the nucleotide sequence in the RNA further defines the amino acid sequence in the protein. This is referred to as “The Central Dogma of Molecular Biology” - a term coined by Francis Crick.  Central dogma is a firm principle in biology that defines the flow of genetic information within any life form. The two fundamental steps in central dogma are - transcription and translation.
Transcription is the synthesis of RNA...
14.6K
Chromatin Position Affects Gene Expression02:35

Chromatin Position Affects Gene Expression

24.9K
Chromatin is the massive complex of DNA and proteins packaged inside the nucleus. The complexity of chromatin folding and how it is packaged inside the nucleus greatly influences  access to genetic information. Generally, the nucleus' periphery is considered transcriptionally repressive, while the cell's interior is considered a transcriptionally active area. 
Topologically Associated Domains (TADs)
The 3-dimensional positioning of chromatin in the nucleus influences the...
24.9K
Gene Flow02:39

Gene Flow

38.0K
Gene flow is the transfer of genes among populations, resulting from either the dispersal of gametes or from the migration of individuals.
38.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Identifying Housing Instability Using Administrative Data: Implications for Research and Advocacy.

Hospital pediatrics·2026
Same author

Multimorbidity Clusters Among People Aged 65 Years and Over in Australia: A Nationwide Cross-Sectional Data Linkage Study.

The Medical journal of Australia·2026
Same author

Impact of Prenatal Cell-Free DNA Screening on Sex Chromosome Aneuploidy Diagnoses in Infants and Children.

Prenatal diagnosis·2026
Same author

Real-World Comparative Effectiveness and Safety of Immune Checkpoint Inhibitors in Advanced Renal Cell Carcinoma: A Systematic Review.

Targeted oncology·2026
Same author

Voriconazole therapy and CYP2C19 phenotype: identifying patients who may need alternative antifungal therapy.

The Journal of antimicrobial chemotherapy·2026
Same author

Ten-Year Public Expenditure Savings Associated with TNF Inhibitor Biosimilars under Australia's Pharmaceutical Benefits Scheme.

Clinical pharmacology and therapeutics·2026

Related Experiment Video

Updated: Feb 10, 2026

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.3K

Insurance Coverage Policies for Pharmacogenomic and Multi-Gene Testing for Cancer.

Christine Y Lu1, Stephanie Loomer2, Rachel Ceccarelli3

  • 1Precision Medicine Translational Research (PROMoTeR) Center, Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, 401 Park Drive, Suite 401 East, Boston, MA 02215, USA. christine_lu@harvardpilgrim.org.

Journal of Personalized Medicine
|May 19, 2018
PubMed
Summary

Insurance coverage for cancer genomic tests varies significantly between Medicare and private payers. Many guideline-recommended tests lack consistent coverage, impacting patient access to precision cancer care.

Keywords:
cancerinsurance coveragemulti-gene testingpharmacogenomicstumor markers

More Related Videos

DNA Vector-based RNA Interference to Study Gene Function in Cancer
13:10

DNA Vector-based RNA Interference to Study Gene Function in Cancer

Published on: June 4, 2012

21.0K
Multi-target Parallel Processing Approach for Gene-to-structure Determination of the Influenza Polymerase PB2 Subunit
22:10

Multi-target Parallel Processing Approach for Gene-to-structure Determination of the Influenza Polymerase PB2 Subunit

Published on: June 28, 2013

13.7K

Related Experiment Videos

Last Updated: Feb 10, 2026

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.3K
DNA Vector-based RNA Interference to Study Gene Function in Cancer
13:10

DNA Vector-based RNA Interference to Study Gene Function in Cancer

Published on: June 4, 2012

21.0K
Multi-target Parallel Processing Approach for Gene-to-structure Determination of the Influenza Polymerase PB2 Subunit
22:10

Multi-target Parallel Processing Approach for Gene-to-structure Determination of the Influenza Polymerase PB2 Subunit

Published on: June 28, 2013

13.7K

Area of Science:

  • Genomic Medicine
  • Health Services Research
  • Oncology

Background:

  • Insurance coverage is crucial for patient access to genomic tests.
  • Pharmacogenomic tests guide cancer treatment decisions.
  • Variations in coverage can create disparities in care.

Purpose of the Study:

  • To analyze and compare insurance coverage policies for guideline-recommended pharmacogenomic tests in cancer care.
  • To identify differences in coverage between Medicare contractors and private payers.
  • To assess the impact of coverage criteria and prior authorization on test accessibility.

Main Methods:

  • Analysis of coverage policies from 8 Medicare contractors and 10 private payers.
  • Inclusion of 23 biomarkers and multi-gene tests relevant to cancer treatment.
  • Extraction of coverage details, criteria, prior authorization requirements, and evidence basis.
  • Review of professional society guidelines for pharmacogenomic test recommendations.

Main Results:

  • Common coverage for KRAS, EGFR, and BRAF tests across payers.
  • Limited coverage for PML/RARA, CD25, and G6PD tests.
  • Medicare coverage policies were consistent, while private payer policies varied.
  • Prior authorization was a common barrier to access among private payers.
  • 13 payers covered multi-gene tests for non-small cell lung cancer based on emerging guidelines.

Conclusions:

  • Coverage policies for cancer genomic tests differ significantly between Medicare and private payers.
  • Inconsistent coverage and use of prior authorization may limit patient access to guideline-recommended pharmacogenomic tests.
  • Further research is needed to understand the impact of coverage variations on cancer care and patient outcomes.